Patrick Donnelly: Okay. And if I can sneak one more in for Ilan, maybe on the margin piece, nice numbers here this year, thinking about 2023. And then, just the path €“ continued path to some of the targets you laid out at the Analyst Day last year. Can you just talked about, I guess, the key levers you have in 2023. And then similarly, as we think about that EBITDA moving towards bigger than 28% number in 2025, those levers that are still left to pull, and some of the restructuring probably comes into play this year. But it’d be helpful just to talk about the moving pieces this year. And then, again, the confidence as we work our way towards that that 28% number.
Ilan Daskal: Sure. Thank you, Patrick. I appreciate the question. So, if you look at the challenges that we experienced in 2022, and we think about 2023, specifically around supply chain constraints, and the impact on elevated cost of raw materials, specifically in higher logistics costs. So as Andy mentioned earlier, we believe it’s going to continue to improve. And that’s part of our thinking in terms of if you think about the gross margin, the improvement of gross margin throughout 2023, specifically in the second half of it. And then when you think about the other internal initiatives that we have in terms of productivity and efficiencies in terms of the restructuring that we completed, and move to Singapore, that is in the final phases of additional manufacturing footprint.
So all these initiatives, we’ll also contribute towards the achievement of the 2025 goals. And that’s kind of what gives us the confidence level that the challenges that we went through in 2022 or more transitory will continue to somewhat €“ to some extent into 2023. But it does not change your thinking about the 2025 model, and the targets that we laid out back in the Investor Day. And, obviously, that comes from the top-line kind of growth drivers that in terms of that you’re aware of.
Patrick Donnelly: Right. Thank you, guys. I appreciate it.
Operator: Thank you. The next question comes from the line of Dan Leonard with Credit Suisse. Please proceed.
Dan Leonard: Hello, thank you for taking the questions. My first question on the 2023 sales guidance, I guess, how important are those second half product launches you mentioned the Continuum and the second generation single-cell instrument? How important are they to the 2023 sales outlook? Or are these more 2024 drivers?
Andrew Last: Yeah, thanks, Dan. They’re not a material contributor in 2023. This is really staging our 2024 revenue ambitions there. So that introductions to the market, but no material contribution.
Dan Leonard: Understood. And, Andy, if possible you can give an update on the Singapore manufacturing transition?
Andrew Last: Yeah, happy to do so. The plant is up and running in Singapore across all the product lines. We’re very pleased with the plant coming up to speed. I would say that the other key consideration here is that we still have our French plants operating. And that is €“ wasn’t our initial plant at this point in time, but we’ve kept them open because of the backorder reduction challenges that we have. And so we’re keeping our plants open through the first half to the end of Q2. And then, we’ll finally close those plants and continue to grow capacity in the Singapore facilities. So at this point, all has moved well, we’ve just had some kind of small diversions, I would say in the past year.
Dan Leonard: Understood. And my final question, this might be related, Ilan, I think you mentioned it would take 8 quarters to normalize inventory. Why would it take so long and is there any opportunity to normalize sooner?
